N-Acetyl-L-azetidin-2-carbonsaeure | 37712-76-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Acetyl-L-azetidin-2-carbonsaeure
• 英文别名: 1-Acetyl-azetidin-2-carbonsaeure；(2S)-1-acetylazetidine-2-carboxylic acid
• CAS: 37712-76-8
• 化学式: C₆H₉NO₃
• 分子量: 143.142
• InChiKey: KGMNLCHUEVFDHL-YFKPBYRVSA-N

物化性质

• 沸点：
  361.7±35.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-Acetyl-L-azetidin-2-carbonsaeure 在 戴斯-马丁氧化剂 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 (2S)-1-acetyl-N-[(1R)-4-[(aminoiminomethyl)amino]-1-(benzothiazolylcarbonyl)butyl]-2-azetidinecarboxamide trifluoroacetate
  参考文献：
  名称：

  Potent, Small-Molecule Inhibitors of Human Mast Cell Tryptase. Antiasthmatic Action of a Dipeptide-Based Transition-State Analogue Containing a Benzothiazole Ketone

  摘要：

  Inhibitors of human mast cell tryptase (EC 3.4.21.59) have therapeutic potential for treating allergic or inflammatory disorders. We have investigated transition-state mimetics possessing a heterocycle-activated ketone group and identified in particular benzothiazole ketone (2S)-6 (RWJ-56423) as a potent, reversible, low-molecular-weight tryptase inhibitor with a K-i value of 10 nM. A single-crystal X-ray analysis of the sulfate salt of (2S)-6 confirmed the stereochemistry. Analogues 12 and 15-17 are also potent tryptase inhibitors. Although RWJ-56423 potently inhibits trypsin (K-i = 8.1 nM), it is selective vs other serine proteases, such as kallikrein, plasmin, and thrombin. We obtained an X-ray structure of (2S)-6 complexed with bovine trypsin (1.9-Angstrom resolution), which depicts inter alia a hemiketal involving Ser-189, and hydrogen bonds with His-57 and Gln-192. Aerosol administration of 6 (2R,2S; RWJ-58643) to allergic sheep effectively antagonized antigen-induced asthmatic responses, with 70-75% blockade of the early response and complete ablation of the late response and airway hyperresponsiveness.

  DOI：

  10.1021/jm030050p
• 作为产物：
  描述：

  乙酸酐 、 (S)-(-)-2-羧基环丁胺 以 二氯甲烷 为溶剂， 生成 N-Acetyl-L-azetidin-2-carbonsaeure
  参考文献：
  名称：

  Energetic contribution to both acidity and conformational stability in peptide models

  摘要：

  酰胺构象异构体的酸度差异已经针对大量的N-乙酰氨基酸进行了修订。

  DOI：

  10.1039/c5nj03611a

文献信息

• Energetic contribution to both acidity and conformational stability in peptide models
  作者：Vladimir Kubyshkin、Patrick Durkin、Nediljko Budisa

  DOI：10.1039/c5nj03611a

  日期：——

  The acidity difference of the amide rotamers has been revised for a large set ofN-acetyl amino acids.

  酰胺构象异构体的酸度差异已经针对大量的N-乙酰氨基酸进行了修订。
• A versatile biosynthetic approach to amide bond formation
  作者：Helena K. Philpott、Pamela J. Thomas、David Tew、Doug E. Fuerst、Sarah L. Lovelock

  DOI：10.1039/c8gc01697f

  日期：——

  The development of versatile and sustainable catalytic strategies for amide bond formation is a major objective for the pharmaceutical sector and the wider chemical industry. Herein, we report a biocatalytic approach to amide synthesis which exploits the diversity of Nature's amide bond forming enzymes, N-acyltransferases (NATs) and CoA ligases (CLs). By selecting combinations of NATs and CLs with

  通用和可持续的酰胺键形成催化策略的开发是制药行业和更广泛的化学工业的主要目标。在这里，我们报告了一种酰胺合成的生物催化方法，该方法利用了自然界中形成酰胺键的酶，N-酰基转移酶（NAT）和CoA连接酶（CL）的多样性。通过选择具有所需底物特征的NAT和CL的组合，可以以可预测的方式构建非天然的生物催化途径，以允许使用化学计量比的羧酸和胺偶联伙伴以高收率获得结构多样的仲和叔酰胺。可以使用分离的酶在体外或体内进行转化反应仅依赖于细胞产生的辅因子。这些全细胞系统的实用性通过Losmapimod的关键中间体（GW856553X）的制备规模合成得到展示，Losmapimod是一种选择性的p38促分裂原活化蛋白激酶抑制剂。
• AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160024064A1

  公开（公告）日：2016-01-28

  The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及一种式（I）的氮杂环酰胺衍生物，其中环A1、A2和A3如说明书所述，其药学上可接受的盐，其制备方法，包含一种或多种式（I）化合物的制药组合物，以及它们作为药物的用途，特别是作为促进睡眠的药物，尤其是作为促进睡眠的药物。
• Process for producing optically active N-substituted azetidine-2-carboxylic acid compound
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP0974670A2

  公开（公告）日：2000-01-26

  There is provided a process for producing an optically active N-substituted azetidine-2-carboxylic acid compound represented by the formula (2): by contacting a corresponding N-substituted azetidine-2-carboxylic acid ester of formula (2) with an enzyme derived from a microorganism selected from Arthrobacter SC-6-98-28 strain, Arthrobacter sp. ATCC21908 strain, Chromobacterium SC-YM-1 strain, and a mutant thereof. A process is also provided for preparing an optically active azetidine-2-carboxylic acid by eliminating the N-substituent of a N-substituted azetidine-2-carboxylic acid ester of formula (2).

  提供了一种生产具有光学活性的 N-取代氮杂环丁烷-2-羧酸化合物的工艺，该化合物由式（2）代表： 将相应的式(2)N-取代的氮杂环丁烷-2-羧酸酯与一种酶接触，该酶来源于一种微生物，该微生物选自节杆菌 SC-6-98-28 株、节杆菌 ATCC21908 株、色杆菌 SC-YM-1 株及其突变体。还提供了一种通过消除式（2）N-取代的氮杂环丁烷-2-羧酸酯的 N-取代基来制备光学活性氮杂环丁烷-2-羧酸的工艺。
• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：EP3166939B1

  公开（公告）日：2019-06-05